Member Info for ScottB93

It had been speculated that the US government shutdown may of affected the processing for the FDA approval. That has now been confirmed. In my opinion this has now certainly moved the timescale of expected approval to at least Q2, if I had to be more specific and with no further delays I'd say most possibly May/June.

Another deal done in Korea, great. However where are the numbers? I want to see what these deals actually correlate to on the bottom line. Surely someone like David Smith with all his experience in this field can understand why investors would want that in business updates?

It's good to see deals still being done and the company progressing, however without numbers to put any of it into context, how do we know how good these deals really are?

Price is at a staggering low now, I have noticed a few sells over the last week or so of quite clearly PI's patience running out. Understandable.

I know it's only February, however there had better be more in the pipeline this year than a few deals with South Korea and just scraping FDA approval before the year end. Next placing is due in August/September 2019 providing nothing unexpected happens. I'm fully expecting the board to be announcing such news to have us trading higher prior to then.

ATB.

Good evening all,

I've been around MRS for going on 2 years now (pre suspension) and have seen it rise to 30p and then to the brink of de-listing; To then come back from that to a profit generating company which is growing at a promising rate. MRS expects this growth to continue into 2019 and from where I'm sat I see no reason why that would not be the case.

Yes there are, as I see it 3 immediate short term issues to be addressed.

1. Debt refinance. Something which is being, as we speak agreed with the specific debtors.
2. Appointment of NOMAD. This one is giving people an itchy sell finger as it would mean suspension if no NOMAD is appointed by 1st February and then potentially delisting on 4th March. Now that is a concern but with the amount the board have invested here (Request a share register to see an up to date account) I find it highly unlikely this would happen.
3. The seller(s). It's very obvious by now that there are multiple large sellers or traders that have eroded away the share price from it's 9.7p high. Now that is a heavy drop of around 60-65% and if you bought in right at the peak then I assume you're rightly frustrated at the moment.

With that said MRS is profit making, and over the next couple of years it is very likely they'll also be debt free. Now if that becomes reality I imagine the share price will reflect it and MRS will be trading at a considerably higher level than now.

It's obvious I do not post on LSE boards frequently as you can tell from my posting history however I'm writing this post to address the spat that is plaguing this forum.

I have come across the poster "troutisout" on other LSE forums and find his posts of great interest and knowledge of the stock in question, hence why I highly respect this poster and continuously learn from this person every time our paths cross.

Greenhills2004 is a poster I cannot recall seeing much of until recently as they post on another LSE forum of which I have an investment. I've never taken issue with them and have nothing against them personally, obviously they have a view to MRS which is different to my own and do not believe the prospects of a promising future here are realistic, which is a completely fine view to have. There is just one thing with that I never understand, why continue to post so frequently on a share you have such a distaste towards?

Spurs777 (A.K.A Dead Stock). A brief look through their posting history reveals the level of immaturity we're dealing with here. I'm not going to start quoting from their history as anyone interested wouldn't have to look far. There is one thing I am very curious about however which I hope they are able to answer is what happened between the dates of 9th May 2018 and the 23rd May 2018 for them to become so bitter about the company?

I'd like to remind people of what David Smith finally officially admitting FDA being delayed to likely Q1 2019 actually means as there seems to be many an impatient P.I here promoting the fact that Q1 2019 is only 2 weeks away.

Now that is very true, however that does not mean FDA is 2 weeks away. Look at what David Smith actually said. They're around 50% of the way through the process of approving FDA. They've had the submission since the end of August, that's 4 months to accomplish 50%. Doing the math on that and providing there isn't a sudden speed up in the process we're realistically looking at having FDA approved by or very close to Q2 2019.

That doesn't need to be a negative reality just a realistic one. P.I need to understand that before taking a position here expecting to have this announced by mid January.

With that said the foundations of IQAI are solid, attracting more attention from private hospitals with contract wins and further increasing popularity of the product. Granted there have been no official figures behind what these contracts are worth which does always play on the back of my mind, however as of right now I have no reason to doubt the board in what they're doing.

ATB.

I'm only going to say this once.

Do not touch this share. For any newcomers to trading this is what is called a spike. Do not get impaled on it.

That is all.

Fantastic news that we have our first commercial sales of stone checker!

This proves that the product has a real world use and there are buyers for it. Hopefully this is the start of many to come but i would like to add that it has taken nearly a year since C/E approval to get our first commercial sales. I hope it will not take as long when we get FDA approval however people should be prepared.

I understand this is a per click model and with kidney stones being such a prominent issue across the globe i can only imagine revenue from the software should be very good. Problem is without figures to back up what the deal is worth we can only speculate.

Does anyone know how much the software charges per click? I remember reading the figures somewhere but for the life of me i cannot remember where.

You've done well to contradict all your posts from October today in regards to this share Cash2. Anyway each to their own and thanks for the transparency. ATB.

Today was the RNS this company needed. Confirms an incredible turning point. Now a profit making company and much of it. Company predict a strong continuation in growth going into 2019. This is now in my opinion a no brainer stock to have in your portfolio.

Afternoon all! Just getting my first post on the new forum! Very bright future ahead now with a name that now represents that! Next news to land should be FDA approval within the next month or so.

Farewell FBDU, Hello IQAI!

A brilliant half year report if i do say so myself!

Very bullish indeed and with the new CEO and Nick Stevens picking up chunky amounts of shares, it says a lot where they think we're headed.

I notice this in the report...

"This dialogue with the FDA has resulted in the adoption of a new predicate software product which the FDA has agreed will result in a more efficient and definitive approach with a clearance decision expected in Q3/4."

A few paragraphs later..

The FDA acknowledged receipt of IB's renewed submission in August 2018. The FDA publicly states its performance goal is to process 510(k) submissions within 90 calendar days and based upon their published results, the majority of decisions are rendered within this period.

So possibly FDA may be delayed slightly to Q4. The lastest possible time being in November at some point.

Post period end, successful completion of £500,000 capital raise at 2.5p ensuring sufficient financial resources for at least the next 12 months.

Fully funded for at least the next 12 months meaning no threat of placings. Company have always been honest and trustworthy on this front.

David Smith, Operating CEO. Strategic overview and introductory statement:

"I have worked in the medical device business for 30 years, and as an entrepreneur in the field for the last 15 years, seeking out opportunities to improve patient healthcare and create outstanding value for shareholders.

I think David and ourselves are going to get along great!

So then, to finish up..

Some of us have been here for over 2 years back when this company was nothing more than a cash shell, so much progress and change has happened since then, none of this never really reflected in share price. However we're now on the home straight. C/E approval in the bag, FDA approval very likely to be awarded in the near term and commercial sales set to commence in Q4, with revenues expected before the end of the year. We are about to enter into the most exciting and promising moments so far for us FBDU holders. 2019 could seriously be that re-rate year we've been waiting for. Don't take my word for it though, look at the director buys over the last couple of days, immediately after the closed period had ended.

If you really want to dream though, how about a buy out by the likes of Google? If we nail this market globally then that could be a very real possibility.

ATB.

I've been very busy the last couple of weeks so not had time to post on the recent developments here.

Placing..

It was always a likely possibility a placing was around the corner anytime after June and here it is. £500k raised to help expand the team at FBDU and develop Imaging Biometrics 2 already FDA approved products. It says the company is growing at an encouraging pace. Also to add at the time of me posting this you can buy under the 2.5p placing price which i believe is brilliant value.

FDA Approval "delay"...

Nick Stevens explaining in his interview on the 23rd July that the FDA submission was resubmitted on advice from the FDA to accelerate approval time should settle uneasy investors. With this only meaning "a 45 day delay" and is still on track for Q3 is very good news. With FDA approval opening up the door the to sales globally, specifically USA India and China Q4 and into Q1 next year could really be explosive for the company.

StoneChecker...

Nick explaining in the same interview that he expects StoneChecker to commence commercial sales in Q4, including in the UK. Personally i am very interested to see who we sign deals with within the UK as there are a lot of potential customers, to name a couple, publicly the NHS would be a massive deal and also privately such companies like Bupa will seriously boost StoneChecker's publicity.

Personally i would like to know how long the placing money will last, or even more excitingly, will this potentially be the last placing as they expect commercial sales from Q4 to generate the required income so placings are no longer required? I'd also like to hear more on this "major player" in the states that was very interested in the StoneChecker product. With FDA approval around the corner is this "mayor player" still a potential customer?

It has been a very long wait from June 2016 when i first invested. FBDU has gone from a cash shell to potentially a global medical supplier. We still have a lot of work to do yet in regards to contract wins. However if Trevor, Nick and the team can nail it by Q4 and commercial sales take off into the new year. We could be looking at a serious return on initial investment.

P.S. Agree fully with SmudgeDan, short/mid term news flow could see us easily back to 4p+ in the near term.

ATB.

Here Draft is again...

Utterly clueless..

This is what the company have actually said, and yes you have been around here long to know this yourself.

In regards to FDA approval... The estimation of this being granted was June at the EARLIEST.

In regards to C/E approval and sales... Granted as predicted in December and some sales have been revealed since. The board of FBDU have NEVER said they would announce every single deal/contract win at they were signed. That is not assuming they have signed more than already announced OR they have not. All we have in regards to this is assumption.

In regards to a potential placing... The company said upon relist back in June last year that they had a significant cash pile which was enough to guarantee a placing would not be necessary for at least 12 months. We have now just about past that 12 month period so yes, realistically a placing is a POSSIBILITY in the near future.

To say FBDU has no catalyst shows your complete ignorance for the company, which is incredible considering how long i know you've been in and out here chasing other rainbows. This is a unique product which has a real world use in the treatment of kidney stones. I never expected much to be announced after C/E approval, rather an update within the half yearly results in which new clients signed and more importantly an update on cash position and whether a placing was upon us, and if so at what price? C/E approval was just a stepping stone to achieving FDA approval in which and i quote the company in saying this "a major player in the states is very interested in our product".

In regards to the dive in price today, yes it has fallen lower than usual. Its normal lowest price is around 3.5p-3.6p. I can only put the out of the ordinary selling today down to investors who have become nervous of a potential incoming placing and the possibility of FDA approval being in their opinion "delayed".

Would not be surprised to see this bounce back towards if not just over 4p as it has done so many times before.

One last thing for Draft, if you're not invested here then don't bother posting. You're clueless about the company and offer nothing to the thread. Concentrate your posts to the URU share forum, that's where your frustration should be carried out with how much of a hole Zorbas has put you in financially.

P.S. Report my post as you did last time i have it copied ready to re-post.

To everyone else still holding. Personally i don't see any immediate reason or worrying concern as to sell. However a placing is possible in the near future going off what the company has communicated with us over the last 14 months or so.

ATB.

Market cap a bit toppy? What a stupid and pointless post. I also know you've been around here long enough draft to know exactly what FBDU has achieved to date and what is potentially around the corner. My only concern is that a placing is a POSSIBILITY here soon unless there has been significant sales since C/E approval. ATB.

Because people don't post frequently doesn't mean investors have done a runner. Been here years and still entirely confident. I don't post if its not necessary. ATB.

.. How about doing forward the board focus on winning GOW contracts instead of messing around loaning money for utter **** investments. Just a thought. Insane how things have gone here, utterly insane! I wish the best for all still invested here. ATB

... A very positive company with a great future, however remember the board said upon relist that they had enough cash to operate for 12 months. That was back in June 2017. Hence possibly a placing coming in the next couple of months. Assuming sales doesn't stave off a placing?

.. This has fallen so far, and still going! I sold the last of my holdings here when the price was 10'000% higher than current levels. There was such promise here with NYW on the build and Jakarta contract "in the near future". A shame really. ATB.

Personally i believe if all stays on track and FDA is approved in the summer, followed by significant interest and sales. A buyout while the company is cheap is a strong possibility before the year is over IMO.

Cash2, taken from your original post... "Sorry I have not been following ukog recently. So I don�t know what has happened. But I was in it when there was talk of oil and gas. It went to 8 p last year." I can only assume English is not your first language so i'll sympathise with you on that. 88e never hit 6p, not even close. Find me a chart and link it here that says otherwise and i'll happily apologise on this forum. Okay, continue posting on a share you yourself admitted you have no idea what is happening. ATB. Recap. Okay so, for anyone who have picked up shares recently here is a quick recap on what has happened and what is anticipated in the near future. C/E approval granted in early December opening the door to deal opportunities across Europe, as updated recently deals are in the process of being signed and i believe a couple of smaller ones already in the bag? Correct me on that if i'm wrong. FDA approval at approximately June 2018, in which a major player in the US has taken a very keen interest in the stone checker software. It has yet to be disclosed who this major player could possibly be, but if you take into account our �2-3M market cap valuation it wouldn't take much to see a multi bagger scenario here. As for the people, myself included who have been invested for the last couple of years we have seen highs as far as 7p, this happened prior to the RTO into stonechecker. It goes to show what can be achieved based on actual contract wins. The share price being sat in the mid 3's is out bottom line, (IMO) it has very rarely fallen further than the current level, hence a good accumulation zone. the board of FBDU never promised an update on every contract/deal win so don't hope for one. Personally i'm more than happy to wait until the summer to get a half yearly report, hopefully with the FDA approval in the bag. This is a strong company with a great CEO at the helm who has done this before, more than once actually. Combine that with a working product and global interest and you're onto a winner. GLA.

Cash2, Probably best not be posting if you have no idea what is going on here, just do some research. UKOG hit 11p not 8p and 88e hit 4.2p not 6p. I don't think you've been following the stocks you say you have at all imo. Now we're back in the 3's we will probably bounce back to mid 4p again sooner rather than later. ATB.